From GlobeNewswire: 2024-04-12 15:00:00

The global Theranostics market size is projected to grow from USD 1.9 billion in 2023 to USD 3.3 billion by 2033, with a CAGR of 5.68%. Theranostics combines medicinal treatment with diagnostics to create more effective medications. The market is driven by the rising incidence of cancer and the need for specialized therapies.

The oncology segment is expected to hold the largest share of the global theranostics market, with a focus on cancer patients. Theranostics uses nanoparticles to target cancer cells and improve treatment efficiency. PCR technology is expected to dominate the market growth, catering to individualized medical solutions in hospitals and clinics.

North America is anticipated to lead the global theranostics market, fueled by the prevalence of chronic diseases and demand for specialized medications. As the market expands, Asia-Pacific is projected to grow rapidly due to the increasing adoption of companion diagnostics for tumors. Major players include F Hoffman La Roche, Thermo Fisher Scientific, and GE Healthcare.

Recent developments in theranostics include collaborations between PharmaLogic and NUCLIDIUM for Cu-based theranostics, and the formation of Radiopharm Ventures, LLC for radiopharmaceutical therapeutic therapies by The University of Texas MD Anderson Cancer Center and Radiopharm Theranostics Limited. The market is segmented by diseases, technology, end-user, and region to provide insights for decision-makers.



Read more at GlobeNewswire: Global Theranostics Market Size To Worth USD 3.3 Billion By